Form 4: BioMarin Pharmaceutical Inc. Executive Erin Burkhart Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Erin Burkhart, GVP and Chief Accounting Officer of BioMarin Pharmaceutical Inc., sold 2,286 shares of common stock at $90 per share on April 10, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On April 10, 2024, Erin Burkhart, the GVP and Chief Accounting Officer of BioMarin Pharmaceutical Inc. (BMRN), sold 2,286 shares of the company's common stock.
- The sale was executed at a price of $90 per share.
- The transaction was conducted under a pre-arranged trading plan pursuant to Rule 10b5-1(c), which was established on November 29, 2023.
- Following the transaction, Burkhart directly owns 16,156 shares of BioMarin common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged plan. It doesn't inherently indicate positive or negative performance for the company.
Industry Context
Sales by company executives are a normal part of corporate governance. The use of a 10b5-1 plan suggests the sale was pre-planned and not based on any inside information.
Stakeholder Impact
- The sale of shares by an executive could be perceived neutrally or slightly negatively by shareholders, depending on their individual investment strategies and perceptions of insider activity.
Key Dates
| Date | Description |
|---|---|
| 2023-11-29 | Date of execution of the 10b5-1 plan. |
| 2024-04-10 | Date of the transaction (stock sale). |
| 2024-04-12 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.